China Approves Wegovy for MASH: What the New Label Means

Novo Nordisk’s September announcement marked a meaningful regulatory expansion for Wegovy in China: the injectable semaglutide product was approved for adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe liver fibrosis. Reporting described it as the first GLP-1 receptor agonist approved in China for MASH.224

What China approved

The Chinese indication applies to non-cirrhotic adults with MASH accompanied by moderate-to-severe liver fibrosis, according to reporting on the National Medical Products Administration’s decision.24 That matters because it positions Wegovy as a treatment in a defined liver-disease setting rather than solely as a medicine associated with weight management.

MASH is an inflammatory form of fatty liver disease associated with metabolic dysfunction. The new indication places Wegovy at the intersection of obesity care and liver care, where metabolic risk factors and liver disease can coexist.

How the approval expands Wegovy’s role

Novo Nordisk said the decision extends the evidence base it has cited for Wegovy from weight management and cardiovascular health to liver health.2 In practical terms, the China label gives clinicians a disease-specific reason to consider injectable semaglutide for eligible MASH patients with fibrosis.

The regulatory move also follows clinical results Novo presented for semaglutide 2.4 mg in MASH. In its investor materials, the company reported that the ESSENCE trial showed superior improvement in both liver fibrosis and MASH resolution versus comparator measures cited in the presentation.44

That does not mean every person with fatty liver disease is eligible for Wegovy under the China approval. The reported label is specific to adults with MASH and moderate-to-severe fibrosis who do not have cirrhosis.24

Why this is different from oral Wegovy in China

The MASH decision concerns injectable Wegovy. It should not be confused with a separate August 2026 regulatory milestone involving the oral version of the drug.

China’s drug regulator accepted Novo Nordisk’s marketing application for oral Wegovy for weight management in August. Acceptance begins the regulatory review process; it is not an approval to market the tablet in China.17 Novo Nordisk had not disclosed a timetable for a final Chinese decision on that oral formulation in the reporting available at the time.17

The clinical significance highlighted in China

Jia Jidong, director of the Liver Disease Center at Beijing Friendship Hospital, described the approval as opening new treatment possibilities for people with MASH. He characterized the shift as moving beyond management of a single risk factor toward simultaneously controlling risks and treating the disease itself.19

That framing captures the importance of the decision: MASH with fibrosis is not simply a weight-management issue, and the new label provides a liver-focused treatment option for the defined patient group.

What it could mean commercially for Novo Nordisk

The approval expands Wegovy’s addressable use in China, but a regulatory label alone does not establish how quickly revenue will follow. The near-term commercial outcome will depend on factors not resolved by the approval itself, including patient access, reimbursement, pricing, prescribing patterns among liver specialists and real-world uptake.

The announcement arrived amid mixed investor assessments. HSBC raised its Novo Nordisk price target to DKK 320 from DKK 300 while retaining a Hold rating, whereas Barclays lowered its target to DKK 300 from DKK 310 and maintained a Neutral/Equal Weight view.93 Those differing actions underline the gap between the strategic value of a broader Wegovy franchise and uncertainty about the company’s near-term growth and execution.

Novo Nordisk was also continuing a share-repurchase programme of up to DKK 15 billion over the 12 months starting February 4, 2026. As of September 4, it had repurchased 32,034,179 B shares for roughly DKK 9.02 billion at an average price of DKK 281.63.30

Bottom line

China’s decision gives Wegovy a new, disease-specific role: treatment of eligible adults with MASH and moderate-to-severe fibrosis. It is an important extension of semaglutide beyond weight management, supported by reported MASH trial evidence and distinguished from the still-pending oral Wegovy application in China.21744

For patients and clinicians, the immediate change is a new approved treatment option within a defined liver-disease population. For Novo Nordisk and investors, the unanswered question is commercial: how rapidly the label translates into reimbursed use and incremental sales in China.